Since most tumor cells overexpress AXL, a tyrosine kinase receptor with oncogenic functions, an RNA aptamer against AXL, GL21.T, has been developed and used to block AXL downstream signaling 18 and to selectively deliver small non-coding RNAs 19-21. Here, AXL is linked to neoplasm.